Marijuana Law, Policy & Reform

Editor: Douglas A. Berman
Moritz College of Law

Monday, August 26, 2019

"Cannabidiol (CBD) in the Therapeutics Industry"

The title of this post is the title of this new paper recently posted to SSRN authored by Sara Goots Blair, a recent graduate of The Ohio State University Moritz College of Law.  This paper is the tenth in an on-going series of student papers supported by Drug Enforcement and Policy Center.  (The nine prior papers in this series are linked below.)  Here is this latest paper's abstract:

Use of Cannabidiol (CBD) in the therapeutics industry has become increasingly popular in the last few years.  CBD rode into public consciousness on the coattails of three booming consumer trends: the herbal supplement industry, the anxiety economy, and the growing legitimate cannabis industry.  However, many uncertainties remain about the legality, safety, and quality of CBD.  The passage of the 2018 Farm Bill legalized hemp production throughout the US, thereby removing hemp-derived CBD from Center for Disease Control and Prevention (CDC)-regulation.  However, the U.S. Food and Drug Administration (FDA) still stakes a claim on regulating dietary supplements and food additives containing CBD.  The sudden legality of CBD, coupled with uncertainty as to its safety, quality, and effectiveness, means it is imperative for states to support research and impose sufficient regulatory oversight over CBD-infused products.

Prior student papers in this series:

https://lawprofessors.typepad.com/marijuana_law/2019/08/cannabidiol-cbd-in-the-therapeutics-industry.html

Business laws and regulatory issues, Federal Marijuana Laws, Policies and Practices, Medical Marijuana Commentary and Debate, Recreational Marijuana Commentary and Debate, Who decides | Permalink

Comments

Post a comment